IFRX logoIFRX
InflaRx N.V.

10,251
Loading...
Loading...
News
all
press releases
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates
InflaRx (IFRX) delivered earnings and revenue surprises of 0.00% and -61.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
chainwire·4mo ago
News Placeholder
Earnings Preview: InflaRx
read more...
Benzinga·10mo ago
News Placeholder
InflaRx N.V. Announces 2024 AGM Details
Inflarx N.V. (IFRX) has released an update. InflaRx N.V. has announced its annual general meeting (AGM) to be held in Amsterdam on April 25, 2024...
TipRanks Financial Blog·1y ago
News Placeholder
InflaRx (NASDAQ:IFRX) Stock Rating Reaffirmed by HC Wainwright
InflaRx (NASDAQ:IFRX Get Free Report)s stock had its buy rating restated by HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They...
Zolmax·1y ago
News Placeholder
Q4 2023 InflaRx NV Earnings Call Transcript
Related Stocks: NAS:IFRX...
GuruFocus·1y ago
News Placeholder
InflaRx reports FY results
InflaRx reports FY results...
SeekingAlpha.com: All News·1y ago
News Placeholder
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR...
Globe Newswire·1y ago
News Placeholder
Earnings Preview: InflaRx
read more...
Benzinga·1y ago

Latest IFRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.